<![CDATA[FDA Accepts NDA for Giredestrant/Everolimus in ESR1-Mutated Breast Cancer]]>
The FDA had accepted a new drug application for giredestrant plus everolimus (Afinitor) for the treatment of patients with estrogen receptor–positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer after progression on previous …